Clinical use of E. coli Nissle 1917 in inflammatory bowel disease - PubMed (original) (raw)
Review
Clinical use of E. coli Nissle 1917 in inflammatory bowel disease
Michael Schultz. Inflamm Bowel Dis. 2008 Jul.
Abstract
The probiotic Escherichia coli strain Nissle 1917 is in addition to some Lactobacilli sp. one of the best-studied probiotic strains. This particular E. coli strain was isolated in 1917 based on its potential to protect from presumably infectious gastroenteritis. Initial therapeutic success was noted in the management of gastrointestinal infectious disorders and infections affecting the urinary tract; the focus shifted later to chronic inflammatory conditions. The unique combination of fitness and survival factors to support intestinal survival, the lack of virulence, and obvious probiotic properties make this microorganism a safe and effective candidate in the treatment of chronic inflammatory bowel diseases. Three large clinical trials have assessed the potential in the maintenance of remission of ulcerative colitis and equivalence to standard 5-ASA medication was documented. This review aims to discuss important mechanisms of E. coli Nissle 1917 and will review the available literature regarding treatment of inflammatory bowel diseases.
Similar articles
- Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
Scaldaferri F, Gerardi V, Mangiola F, Lopetuso LR, Pizzoferrato M, Petito V, Papa A, Stojanovic J, Poscia A, Cammarota G, Gasbarrini A. Scaldaferri F, et al. World J Gastroenterol. 2016 Jun 28;22(24):5505-11. doi: 10.3748/wjg.v22.i24.5505. World J Gastroenterol. 2016. PMID: 27350728 Free PMC article. Review. - Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Petersen AM, et al. J Crohns Colitis. 2014 Nov;8(11):1498-505. doi: 10.1016/j.crohns.2014.06.001. Epub 2014 Jun 25. J Crohns Colitis. 2014. PMID: 24972748 Clinical Trial. - Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Kruis W, et al. Gut. 2004 Nov;53(11):1617-23. doi: 10.1136/gut.2003.037747. Gut. 2004. PMID: 15479682 Free PMC article. Clinical Trial. - Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications.
Zhao Z, Xu S, Zhang W, Wu D, Yang G. Zhao Z, et al. Food Funct. 2022 Jun 6;13(11):5914-5924. doi: 10.1039/d2fo00226d. Food Funct. 2022. PMID: 35583304 Review. - [The role of Escherichia coli strain Nissle 1917 in the gastro-intestinal diseases].
Różańska D, Regulska-Ilow B, Choroszy-Król I, Ilow R. Różańska D, et al. Postepy Hig Med Dosw (Online). 2014 Nov 6;68:1251-6. doi: 10.5604/17322693.1127882. Postepy Hig Med Dosw (Online). 2014. PMID: 25380207 Review. Polish.
Cited by
- The application of bacteria-nanomaterial hybrids in antitumor therapy.
Xiao S, Mu M, Feng C, Pan S, Chen N. Xiao S, et al. J Nanobiotechnology. 2024 Sep 4;22(1):536. doi: 10.1186/s12951-024-02793-x. J Nanobiotechnology. 2024. PMID: 39227831 Free PMC article. Review. - Priority order of neonatal colonization by a probiotic or pathogenic Escherichia coli strain dictates the host response to experimental colitis.
Hudcovic T, Petr Hermanova P, Kozakova H, Benada O, Kofronova O, Schwarzer M, Srutkova D. Hudcovic T, et al. Front Microbiol. 2024 Aug 14;15:1393732. doi: 10.3389/fmicb.2024.1393732. eCollection 2024. Front Microbiol. 2024. PMID: 39206364 Free PMC article. - Engineering a Novel Probiotic Toolkit in Escherichia coli Nissle 1917 for Sensing and Mitigating Gut Inflammatory Diseases.
Weibel N, Curcio M, Schreiber A, Arriaga G, Mausy M, Mehdy J, Brüllmann L, Meyer A, Roth L, Flury T, Pecina V, Starlinger K, Dernič J, Jungfer K, Ackle F, Earp J, Hausmann M, Jinek M, Rogler G, Antunes Westmann C. Weibel N, et al. ACS Synth Biol. 2024 Aug 16;13(8):2376-2390. doi: 10.1021/acssynbio.4c00036. Epub 2024 Aug 8. ACS Synth Biol. 2024. PMID: 39115381 Free PMC article. - A Review of the Mechanisms of Bacterial Colonization of the Mammal Gut.
Lin Q, Lin S, Fan Z, Liu J, Ye D, Guo P. Lin Q, et al. Microorganisms. 2024 May 19;12(5):1026. doi: 10.3390/microorganisms12051026. Microorganisms. 2024. PMID: 38792855 Free PMC article. Review. - Genetically Engineered Microorganisms and Their Impact on Human Health.
Mahdizade Ari M, Dadgar L, Elahi Z, Ghanavati R, Taheri B. Mahdizade Ari M, et al. Int J Clin Pract. 2024 Mar 9;2024:6638269. doi: 10.1155/2024/6638269. eCollection 2024. Int J Clin Pract. 2024. PMID: 38495751 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources